RECURSION PHARMACEUTICALS, INC.
For the period ended Sep 30, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 2, 2026
RXRX$3.81+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
Exhibit Index:
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit number · Description · Form · File No. · Exhibit No. · Filing Date · Filed / Furnished Herewith | |||||
| 2.1* | Transaction Agreement by and between Recursion Pharmaceuticals, Inc. and Exscientia plc dated as of August 8, 2024. | 8-K | 001-40323 | 2.1 | August 8, 2024 |
| 3.1 | Amended and Restated Certificate of Incorporation of Recursion Pharmaceuticals, Inc. | 8-K | 001-40323 | 3.1 | April 21, 2021 |
| 3.2 | Amended and Restated Bylaws of Recursion Pharmaceuticals, Inc. | 8-K | 001-40323 | 3.1 | January 31, 2024 |
| 4.1 | Specimen Class A common stock certificate of the Registrant. | S-1/A | 333-254576 | 4.2 | April 15, 2021 |
| 4.2 | Exchangeable Share Support Agreement, dated May 8, 2023. | S-3ASR | 333-272281 | 4.2 | May 30, 2023 |
| 4.3 | Registration Rights Agreement, dated October 24, 2022, by and among the Company and the Purchasers. | 8-K | 001-40323 | 10.2 | October 25, 2022 |
| 4.4 | Registration Agreement, dated May 16, 2023, by and among the Registrant, Valence Discovery, Inc., and certain shareholders of Valence Discovery, Inc. | S-3ASR | 333-272281 | 4.3 | May 30, 2023 |
| 4.5 | Registration Agreement, dated May 25, 2023, by and among the Registrant, Recursion Canada Inc., and certain shareholders of Cyclica Inc. | 8-K | 001-40323 | 4.1 | June 9, 2023 |
| 4.6 | Registration Rights Agreement, dated July 11, 2023, by and among the Registrant and NVIDIA. | 8-K | 001-40323 | 10.2 | July 12. 2023 |
| 10.1 | Amendment to the Master Agreement between the Company and Tempus AI, Inc. dated August 4, 2026. | X |
| 10.2#* | Amendment to the Master Agreement between the Company and Tempus AI, Inc. dated September 15, 2026. | X |
| 10.3#* | RNA Foundation Model License Agreement between the Company and Tempus AI, Inc. dated November 3, 2023, as amended. | X |
| 10.4* | Eleventh Amendment to the Office Lease by and between Vestar Gateway, LLC and Registrant, dated July 31, 2026. | X |
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X |
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X |
| 32.1** | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X |
| 101.INS | XBRL Instance Document | X |
| 101.SCH | XBRL Taxonomy Extension Schema Document | X |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | X |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | X |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document | X |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | X |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | X |
| + | Indicates a management contract or compensatory plan. | |
| # | Portions of the exhibit, marked by brackets and asterisks [***], have been omitted because the omitted information is not material and (i) would likely cause competitive harm to the registrant if publicly disclosed or (ii) is information that the registrant treats as private or confidential. | |
| * | Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished. | |
| ** | The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.